Get the Stockscreener App
47.31
0.64%
0.30
Qiagen Nv stock is traded at $47.31, with a volume of 1.69M.
It is up +0.64% in the last 24 hours and up +0.64% over the past month.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by EMEA (33%), and the Asia-Pacific (15%).
See More
Previous Close:
$47.01
Open:
$47.12
24h Volume:
1.69M
Relative Volume:
1.43
Market Cap:
$10.26B
Revenue:
$2.04B
Net Income/Loss:
$373.39M
P/E Ratio:
27.89
EPS:
1.6961
Net Cash Flow:
$495.96M
1W Performance:
+5.20%
1M Performance:
+0.64%
6M Performance:
-0.46%
1Y Performance:
+2.35%
1-Day Range:
$46.78
$47.57
1-Week Range:
$44.71
$47.57
52-Week Range:
$37.74
$51.88
Qiagen Nv Stock (QGEN) Company Profile
Compare QGEN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
QGEN
Qiagen Nv
|
47.31 | 10.19B | 2.04B | 373.39M | 495.96M | 1.6961 |
|
TMO
Thermo Fisher Scientific Inc
|
617.15 | 233.21B | 43.74B | 6.58B | 6.11B | 17.31 |
|
DHR
Danaher Corp
|
235.57 | 167.12B | 24.27B | 3.50B | 5.02B | 4.8589 |
|
IDXX
Idexx Laboratories Inc
|
714.55 | 56.44B | 4.17B | 1.03B | 940.22M | 12.61 |
|
A
Agilent Technologies Inc
|
147.81 | 41.84B | 6.95B | 1.30B | 1.15B | 4.5696 |
|
IQV
Iqvia Holdings Inc
|
244.29 | 40.96B | 15.90B | 1.28B | 2.21B | 7.2842 |
Qiagen Nv Stock (QGEN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-11-25 | Downgrade | Citigroup | Buy → Neutral |
| Jun-24-25 | Initiated | Barclays | Overweight |
| Apr-04-25 | Downgrade | Redburn Atlantic | Buy → Neutral |
| Feb-19-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jan-06-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-10-24 | Upgrade | Jefferies | Hold → Buy |
| Oct-17-24 | Downgrade | HSBC Securities | Buy → Hold |
| Jun-27-24 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Dec-19-23 | Initiated | Wells Fargo | Equal Weight |
| Dec-13-23 | Initiated | Wolfe Research | Peer Perform |
| Dec-07-23 | Upgrade | Goldman | Neutral → Buy |
| Sep-12-23 | Initiated | Robert W. Baird | Outperform |
| May-23-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-18-22 | Initiated | Morgan Stanley | Equal-Weight |
| Jan-18-22 | Upgrade | DZ Bank | Hold → Buy |
| Oct-15-21 | Resumed | Cowen | Market Perform |
| Oct-14-21 | Initiated | Redburn | Buy |
| Jul-14-21 | Downgrade | Kepler | Buy → Hold |
| Jun-03-21 | Initiated | Goldman | Neutral |
| Oct-06-20 | Resumed | BofA Securities | Buy |
| Sep-28-20 | Upgrade | Kepler | Hold → Buy |
| Aug-24-20 | Upgrade | Citigroup | Neutral → Buy |
| Aug-20-20 | Resumed | JP Morgan | Overweight |
| Aug-17-20 | Upgrade | Berenberg | Hold → Buy |
| Aug-14-20 | Upgrade | Deutsche Bank | Hold → Buy |
| Aug-14-20 | Upgrade | Exane BNP Paribas | Neutral → Outperform |
| Mar-04-20 | Downgrade | Berenberg | Buy → Hold |
| Jan-08-20 | Initiated | Wells Fargo | Equal Weight |
| Jan-07-20 | Initiated | Citigroup | Neutral |
| Dec-26-19 | Resumed | BofA/Merrill | Underperform |
| Nov-15-19 | Initiated | Stifel | Hold |
| Nov-14-19 | Upgrade | Evercore ISI | In-line → Outperform |
| Nov-14-19 | Upgrade | JP Morgan | Underweight → Overweight |
| Nov-14-19 | Upgrade | Kepler | Reduce → Hold |
| Oct-17-19 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Oct-09-19 | Downgrade | Kepler | Hold → Reduce |
| Oct-08-19 | Downgrade | Barclays | Overweight → Equal Weight |
| Oct-08-19 | Downgrade | Deutsche Bank | Buy → Hold |
| Oct-08-19 | Downgrade | JP Morgan | Neutral → Underweight |
View All
Qiagen Nv Stock (QGEN) Latest News
Qiagen NV To Go Ex-Dividend On January 8th, 2026 With 2.29 USD Dividend Per Share And 19-for-20 Reverse Stock Split - 富途牛牛
Gateway Investment Advisers LLC Takes Position in Qiagen N.V. $QGEN - MarketBeat
Generali Asset Management SPA SGR Increases Holdings in Qiagen N.V. $QGEN - MarketBeat
Qiagen and Gencurix partner for oncology tests - MSN
Weekly Trades: Why Qiagen NV Common Shares stock trades below fair valueJuly 2025 Momentum & Low Risk High Win Rate Stock Picks - moha.gov.vn
Qiagen N.V. (NYSE:QGEN) is a favorite amongst institutional investors who own 82% - Yahoo Finance
Qiagen N.V.: Quiet Accumulation Or Fading Momentum? A Deep Look At The Stock Behind Molecular Diagno - AD HOC NEWS
Allspring Global Investments Holdings LLC Raises Holdings in Qiagen N.V. $QGEN - MarketBeat
Reproductive Genetics Market Size to Reach USD 16.67 Billion in 2032 Amid Increasing Demand for Genetic Testing - GlobeNewswire Inc.
Burney Co. Purchases Shares of 38,699 Qiagen N.V. $QGEN - MarketBeat
Qiagen sees synthetic share repurchase completed in January - MSN
Qiagen (NYSE:QGEN) Shares Set to Reverse Split on Thursday, January 8th - MarketBeat
Qiagen N.V. (NYSE:QGEN) Given Average Rating of "Hold" by Analysts - MarketBeat
Qiagen NV To Carry Out 19-for-20 Reverse Stock Split On January 8th, 2026 - 富途牛牛
Qiagen N.V. $QGEN Shares Sold by Voya Investment Management LLC - MarketBeat
Qiagen (NYSE:QGEN) Rating Increased to Buy at Wall Street Zen - MarketBeat
Growth Value: Is ONE Gas Inc OG9 stock attractive for dividend growthWeekly Stock Report & Weekly High Momentum Picks - moha.gov.vn
What Wall Street predicts for Qiagen N.V. stock priceQuarterly Profit Summary & Daily Growth Stock Investment Tips - Улправда
How Qiagen N.V. stock performs in rising dollar environment2025 Year in Review & Stepwise Entry and Exit Trade Signals - bolumsonucanavari.com
Qiagen’s US$500 Million Synthetic Buyback Might Change The Case For Investing In Qiagen (QGEN) - Sahm
What sentiment indicators say about Qiagen N.V. stockTake Profit & Safe Capital Growth Tips - Улправда
Whale Trades: How buybacks impact Qiagen N.V. stock valueJuly 2025 Short Interest & Safe Entry Momentum Tips - Улправда
Can Qiagen N.V. stock beat market expectations this quarter2025 EndofYear Setup & Expert Approved Trade Ideas - DonanımHaber
Can Qiagen N.V. Common Shares stock sustain revenue momentum2025 Support & Resistance & Real-Time Chart Breakout Alerts - DonanımHaber
Why Qiagen N.V. stock is recommended by analysts2025 Trade Ideas & Long-Term Growth Stock Strategies - Bölüm Sonu Canavarı
Aug Sectors: How interest rate cuts could boost Qiagen N.V. stockM&A Rumor & Smart Allocation Stock Reports - Улправда
Trend Review: Can Qiagen NV stock maintain growth trajectoryJuly 2025 Intraday Action & Stepwise Trade Execution Plans - moha.gov.vn
[6-K] QIAGEN N.V. Current Report (Foreign Issuer) | QGEN SEC FilingForm 6-K - Stock Titan
Published on: 2025-12-19 07:09:16 - Улправда
Published on: 2025-12-19 04:35:20 - Улправда
Qiagen Details on Completion of $500 Million Synthetic Share Repurchase - 富途牛牛
QIAGEN Announces Details for Completion of Synthetic Share Repurchase of up to Approximately $500 Mi - PharmiWeb.com
Qiagen price target raised to $55 from $53 at Barclays - MSN
QIAGEN to return $500 million to shareholders through share repurchase By Investing.com - Investing.com Nigeria
QIAGEN Announces Details For Completion Of Synthetic Share Repurchase Of Up To Approximately $500 Million >QGEN - 富途牛牛
QIAGEN to return $500 million to shareholders through share repurchase - Investing.com
Qiagen announces details for completion of synthetic share repurchase of up to approximately $500 mln - marketscreener.com
QIAGEN Announces Details for Completion of Synthetic Share Repurchase of up to Approximately $500 Million - marketscreener.com
What analyst consensus says on Qiagen N.V. stock2025 Retail Activity & Smart Allocation Stock Tips - ulpravda.ru
QIAGEN NV receives notification on voting rights from AFM - MSN
Does Qiagen Offer Long Term Value After Recent Precision Medicine Investments? - Sahm
Key facts: Goldman Sachs Reports Holdings in QIAGEN, American Axle, Qualcomm - TradingView — Track All Markets
Tangible book value per share of QIAGEN NV – EUROTLX:4QGEN - TradingView — Track All Markets
Barclays Maintains Qiagen N.V. (QGEN) Overweight Recommendation - Nasdaq
QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG - Pressetext
AlphaValue/Baader Europe Ups Qiagen EPS Estimates on Operational Performance Beat - MarketScreener
Morgan Stanley Maintains Qiagen NV(QGEN.US) With Hold Rating, Cuts Target Price to $49.36 - 富途牛牛
QIAGEN Announces Significant Goldman Sachs Transaction Notification - TipRanks
QIAGEN N.V. Receives Notification on Voting Rights from AFM - TipRanks
Barclays Raises Price Target for QGEN to $55.00 While Maintainin - GuruFocus
PTA-PVR: QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG - TradingView — Track All Markets
Qiagen Nv Stock (QGEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.56%
2.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):